MENLO PARK, Calif., July 16 Today, Apieron, Inc. reported that it filed a patent infringement complaint against Aerocine AB, Solna, Sweden, Aerocrine AG, Bad Homburg, Germany and Mr. Mangus Pelles, Usingen, Germany in the Regional Court of Mannheim, Germany. Apieron, makers of the Insight(TM) eNO System for measurement of exhaled nitric oxide, presented this complaint against Aerocrine on the grounds that they are offering and putting on the market portable and stationary analyzers to detect the nitric oxide content in breath, which Apieron considers to be infringing the German part of its European Patent EP 0 892 926.
About Apieron, Inc.
Apieron, Inc. is a private venture-backed medical device company dedicated to developing innovative solutions to improve the standard of care for people with asthma. Its Insight(TM) eNO System measures exhaled nitric oxide (eNO) which is a well established indicator of airway inflammation for asthma management. Utilizing a proprietary biosensor, Apieron's Insight eNO System can detect trace amounts of nitric oxide in a patient's breath. It is highly accurate, non-invasive, safe, easy to use, and provides results in less than a minute.
Contact: Steve DiMattia (646) 201-5445
SOURCE Apieron, Inc.